Cannara Biotech Inc. (TSX:LOVE)
Canada · Delayed Price · Currency is CAD | Market Cap | 201.38M +29.4% |
| Revenue (ttm) | 117.33M +14.8% |
| Net Income | 10.86M -30.0% |
| EPS | 0.11 -35.3% |
| Shares Out | 98.72M |
| PE Ratio | 18.56 |
| Forward PE | 11.45 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 24,187 |
| Open | 2.170 |
| Previous Close | 2.090 |
| Day's Range | 2.040 - 2.170 |
| 52-Week Range | 1.550 - 2.370 |
| Beta | 0.32 |
| Analysts | Strong Buy |
| Price Target | 3.38 (+65.44%) |
| Est. Earnings | Nov 24, 2026 |
About Cannara Biotech
Cannara Biotech Inc., together with its subsidiaries, engages in the indoor cultivation, processing, and sale of cannabis and cannabis-derivative products in Canada. The company operates in two segment Cannabis operations and Real estate operations. It offers its products under TRIBAL, nugz, and ORCHID CBD brand name. The company sells its products through wholesalers and online merchandisers. In addition, it engages in the real estate operations. Cannara Biotech Inc. was incorporated in 2017 and is headquartered in Saint-Laurent, Canada. [Read more]
Full Company ProfileFinancial Performance
In fiscal year 2025, Cannara Biotech's revenue was 107.20 million, an increase of 31.14% compared to the previous year's 81.75 million. Earnings were 13.08 million, an increase of 103.09%.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for LOVE stock is "Strong Buy." The 12-month stock price target is $3.38, which is an increase of 65.44% from the latest price.
News
Cannara Biotech Transcript: Planet MicroCap Showcase: Toronto 2026
Recent results showed nearly CAD32m net revenue and over CAD8.5m adjusted EBITDA at a 27% margin, alongside 21 consecutive quarters of positive adjusted EBITDA. A CAD30m FY2027 expansion and enlarged Curaleaf agreement support capacity-led growth.
Cannara Biotech price target raised to C$4 from C$3.25 at TD Securities
TD Securities raised the firm’s price target on Cannara Biotech (LOVFF) to C$4 from C$3.25 and keeps a Buy rating on the shares.
Cannara Biotech Earnings Call Transcript: Q3 2026
Gross cannabis revenue grew 16% year-over-year to CAD 44.1 million, with net income of CAD 4.8 million and adjusted EBITDA up 11%. Market share gains in Ontario and Alberta, strategic acquisitions, and a CAD 21 million Curaleaf deal support accelerated capacity expansion and international growth.
Cannara Biotech Earnings release: Q3 2026
Cannara Biotech released its Q3 2026 earnings on July 15, 2026, summarizing the period's financial results.
Cannara Biotech MD&A: Q3 2026
Cannara Biotech filed a regulatory document on July 15, 2026 disclosing important business information.
Cannara Biotech Report: Q3 2026
Cannara Biotech published a report on July 15, 2026 containing material business information for investors and shareholders.
Cannara Biotech Slides: Q3 2026
Cannara Biotech has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on July 15, 2026.
Cannara Reports Record Q3 Revenues and Continued Profitability Accompanied By Expanding National Distribution and Accelerated Capacity Expansion
Cannara reports record Q3 2026 revenue, continued profitability, broader national distribution and accelerated capacity expansion to meet growing demand.
Cannara Biotech Slides: Investor presentation
Cannara Biotech has posted slides in relation to its latest quarterly earnings report, which was published on July 15, 2026.
Cannara Biotech Transcript: Planet MicroCap Las Vegas 2026
Operational scale and disciplined expansion have driven strong margins, consistent profitability, and market leadership in Quebec, with plans to double production and complete major CapEx projects by 2027. International opportunities are being explored, but Canadian growth remains the near-term focus.
Cannara Biotech Earnings Call Transcript: Q2 2026
Q2 saw revenue rise to CAD 27.2M with strong margins and market share gains, especially in Quebec, despite industry seasonality. Strategic investments, new product launches, and capacity expansion position the business for continued growth and international opportunities.
Cannara Biotech Report: Q2 2026
Cannara Biotech published a report on April 14, 2026 containing material business information for investors and shareholders.
Cannara Biotech MD&A: Q2 2026
Cannara Biotech filed a regulatory document on April 14, 2026 disclosing important business information.
Cannara Biotech Earnings release: Q2 2026
Cannara Biotech released its Q2 2026 earnings on April 14, 2026, summarizing the period's financial results.
Cannara Reports Q2 Fiscal 2026 Results with Continued Profitability, Strong Operating Cash Flow and #1 Retail Market Share in Québec
Cannara Releases Q2 FY26 Results: $27.2M revenue, 43% GM, $6.0M Adj. EBITDA, OCF $2.9M; 4.4% national share, #1 Québec; Valleyfield expansion progressing.
Cannara Biotech Slides: Investor presentation
Cannara Biotech has posted slides in relation to its latest quarterly earnings report, which was published on April 14, 2026.
Video - CEO Clips: Cannara Biotech Graduates to Toronto Stock Exchange
Vancouver, British Columbia--(Newsfile Corp. - March 19, 2026) - Cannara Biotech Inc. (TSX: LOVE) (OTCQX: LOVFF) (FSE: 8CB0) is a vertically integrated producer of affordable premium-grade cannabis an...
Cannara Biotech Inc. (LOVE) Opens the Market
Toronto, Ontario--(Newsfile Corp. - March 17, 2026) - Donald Olds, Lead Director and Chairman of the Audit and Governance Committee, Cannara Biotech Inc. ("Cannara" or the "Company") (TSX: LOVE), toge...
Cannara Biotech Slides: Investor presentation
Cannara Biotech has posted slides in relation to its latest quarterly earnings report, which was published on March 1, 2026.
Cannara Biotech graduates to TSX
Cannara Biotech (LOVFF) received final approval to graduate from the TSX Venture Exchange to the Toronto Stock Exchange. In connection with the Uplisting, the Company’s common shares will commence tra...
Cannara Biotech initiated with a Buy at TD Securities
TD Securities analyst Derek Lessard initiated coverage of Cannara Biotech (LOVFF) with a Buy rating and C$3.25 price target calling it the firm’s “top pure-play recreational Canadian LP pick.” Cannara...
Cannara Biotech Transcript: Status update
Disciplined growth, strong brand portfolio, and operational efficiency have driven rising market share and profitability, with a clear, capital-efficient expansion plan and robust financials. Strategic capital raises and TSX uplisting aim to enhance liquidity and investor access.
Cannara Biotech prices 3M shares at C$2.10 in private placement
Cannara Biotech (LOVFF) completed a strategic, non-brokered private placement with Phoenician Capital. Pursuant to the terms of a subscription agreement, Phoenician has agreed to subscribe for 3,000,0...
Cannara Biotech announces conditional approval to list on TSX
Cannara Biotech (LOVFF) has received conditional approval to uplist its common shares to the Toronto Stock Exchange from the TSX Venture Exchange.
Cannara Biotech reports Q1 EPS C$0.01 vs. C$0.03 last year
Reports Q1 revenue C$30.1M vs. $25.1M last year. “Our continued market share expansion in Q1 2026 reflects the strength of our brands and our disciplined approach to growth,” said Zohar…